MD

ANAVEX®2–73 (Blarcamesine) Phase 2B/3 Study Met Primary and Key Secondary Endpoints, Showing Statistically Significant Reduction of Clinical Decline in Global Clinical Study of Patients With Early Alzheimer’s Disease

Retrieved on: 
Friday, December 2, 2022
Principal investigator, Congress, Safety, Amyloid, ITT, Nature, Research, Cancer, Clinical trial, Neurodegeneration, Dizziness, Parkinson's disease dementia, Patient, MCI, Caregiver, Drug development, Dementia, Quality of life, Mouse, Government budget balance, ADAS-Cog, Nursing, Parkinson's disease, Central nervous system, CNS, Trial of the century, Annual report, Met, SIGMAR1, Cognition, The Michael J. Fox Foundation, Degenerative disease, Epilepsy, ECG, Central nervous system disease, Pain, AD, Death, Hospice, MPH, FRANZCP, Incidence, Communication, Rett syndrome, Therapy, Vital signs, Odds ratio, Clinical Dementia Rating, Medical imaging, Pharmaceutical industry, Fine chemical, Vaccine, Alzheimer's disease, Doctor of Philosophy, MD

ANAVEX2-73 met the primary endpoints ADAS-Cog1 and ADCS-ADL2 and key secondary endpoint CDR-SB3 with statistically significant results.

Key Points: 
  • ANAVEX2-73 met the primary endpoints ADAS-Cog1 and ADCS-ADL2 and key secondary endpoint CDR-SB3 with statistically significant results.
  • ANAVEX2-73 treatment met the primary endpoints and reduced clinical decline on the global cognitive and functional scales over 48 weeks in the analysis of the Intent-to-treat (ITT) population.
  • ANAVEX2-73 demonstrated visible improvement in patients with Alzheimers disease.
  • On average, patients, who improved cognitively with ANAVEX2-73 treatment, improved by ADAS-Cog cognition score of -4.03 points.

Ideaventions Academy wins 1st Place in Advanced Vertical Robotics Competition

Retrieved on: 
Friday, December 2, 2022
Student, Mathematics, AVR, MD, Water, Engineering, Bell, Daedalus Project, Management, Science, School

RESTON, Va., Dec. 1, 2022 /PRNewswire-PRWeb/ -- Ideaventions Academy "Daedalus" team from Reston, Virginia, won first place in the northeast regional Bell Advanced Vertical Robotics (AVR) competitions held on November 19 and 20th in Owings Mills, MD, earning them a spot at the National AVR competition on December 3 in Arlington, Texas.

Key Points: 
  • Ideaventions Academy "Daedalus" team from Reston, Virginia, won first place at the northeast regional Bell Advanced Vertical Robotics (AVR) competitions held on November 19 and 20th in Owings Mills, MD, earning them a spot at the National AVR competition on December 3 in Arlington, TX.
  • This is the first year that the Ideaventions team, comprised of students in grades 7 - 11, participated in the Bell AVR program.
  • RESTON, Va., Dec. 1, 2022 /PRNewswire-PRWeb/ -- Ideaventions Academy "Daedalus" team from Reston, Virginia, won first place in the northeast regional Bell Advanced Vertical Robotics (AVR) competitions held on November 19 and 20th in Owings Mills, MD, earning them a spot at the National AVR competition on December 3 in Arlington, Texas.
  • Offering a personalized, rigorous, and engaging STEM-focused education, Ideaventions Academy is preparing students for top colleges and to be future leaders in STEMfields.

UPDATE: Cornerstone Specialty Network Hosts a Successful Community Oncology Focused Data Review Meeting: October 2022

Retrieved on: 
Thursday, December 1, 2022
Health, European Society for Medical Oncology, Oncology, Research, Mayo Clinic, Community Oncology Alliance, Symposia, HCPS, ESMO, Medicine, MD, HOPE

The Cornerstone Data Review Symposia are a unique and valuable series of programs offered to community oncology healthcare providers (HCPs); they summarize thelatestclinical data that immediately impactspractice patternsin the community oncologysetting.

Key Points: 
  • The Cornerstone Data Review Symposia are a unique and valuable series of programs offered to community oncology healthcare providers (HCPs); they summarize thelatestclinical data that immediately impactspractice patternsin the community oncologysetting.
  • In addition to the ESMO Data Review Meeting, Cornerstone Specialty Network also hosts the following data review meetings:
    Cornerstone Oncology Fellowship Advancement Initiative (COFAI) - Specifically customized for oncologists who are new to the community setting with the goal of accelerating quality patient care.
  • To view any of the data review meetings, please visit https://www.cornerstoneoncology.com/events/
    Cornerstone Specialty Network, LLC is the leading provider of long-term, sustainable value through an aggregated network of Community Oncology practices.
  • Through network aggregation, Cornerstone Specialty Network delivers value-added opportunities that support independence and long-term sustainability for community oncology practices.

Blue Earth Diagnostics Announces Efficacy and Safety Results from Phase 3 LIGHTHOUSE Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Newly Diagnosed Prostate Cancer

Retrieved on: 
Thursday, December 1, 2022
Biotechnology, Health, General Health, Radiology, Pharmaceutical, Oncology, Other Science, Medical Devices, Research, Science, Clinical Trials, Associate professor, Prostate cancer, Safety, Radiopharmaceutical, CEUS, Cancer, PET, Regulation of tobacco by the U.S. Food and Drug Administration, Magnetic resonance, University, PLN, Health, Therapy, Trial of the century, RP, MD Anderson Cancer Center, MRI, Cardiac catheterization, Prostate, Multimedia, Acquisition, New Drug Application, Technical University of Munich, Interventional radiology, CT, Google Images, MD, Dissection, Institute of technology, Molecular imaging, Recurrence, Nuclear medicine, SUO, Magnetic resonance imaging, Food, Precision medicine, EAP, 3D ultrasound, Division, Prognosis, Isotope, PSMA, Membrane, Risk, Medical imaging, Patient

The Phase 3 LIGHTHOUSE clinical study investigated the diagnostic performance of 18F-rhPSMA-7.3 PET imaging as a decision-making aid in assessing newly diagnosed prostate cancer in patients with unfavorable intermediate-, high- or very high-risk disease.

Key Points: 
  • The Phase 3 LIGHTHOUSE clinical study investigated the diagnostic performance of 18F-rhPSMA-7.3 PET imaging as a decision-making aid in assessing newly diagnosed prostate cancer in patients with unfavorable intermediate-, high- or very high-risk disease.
  • The LIGHTHOUSE Phase 3 clinical trial was a prospective, Phase 3, multi-center, single-arm, imaging study investigating the safety and diagnostic performance of 18F-rhPSMA-7.3 Positron Emission Tomography (PET) in men with newly diagnosed prostate cancer.
  • Blue Earth Diagnostics has completed two Phase 3 clinical studies evaluating the safety and diagnostic performance of 18F-rhPSMA-7.3 PET imaging in prostate cancer: (SPOTLIGHT, NCT04186845 ), in men with recurrent disease and (LIGHTHOUSE, NCT04186819 ), in men with newly diagnosed prostate cancer.
  • In 2021, Bracco Imaging established Blue Earth Therapeutics as a separate, cutting-edge biotechnology vehicle to develop radiopharmaceutical therapies.

VirTech Bio presenting at the Florida Venture Summit Dec. 6, 2022

Retrieved on: 
Thursday, December 1, 2022
Multiplicity (chemistry), Science, Blood, HBOC, IND, MM, Hypovolemia, CGMP, Death, MD, Bleeding, Patent, Medicine, United States Department of Defense, Medical device, Pharmaceutical industry

Dr. Hack became CEO of VirTech Bio in March 2022.

Key Points: 
  • Dr. Hack became CEO of VirTech Bio in March 2022.
  • VirTech Bio has previously raised seed funding of $6.7 MM which leverages $13.7 MM awarded in non-dilutive funding to date, primarily from the DoD.
  • The Florida Venture Summit is being held in Miami (Dec. 6 -7, 2022) and is billed as a premier event 'Where Innovation Meets Capital'.
  • For more information about VirTech Bio contact us at: [email protected] .

NUROSENE BUSINESS UPDATE

Retrieved on: 
Thursday, December 1, 2022
Molecule, Machine learning, Doctor of Philosophy, Stroke, OTC, Tufts University, Conversation, Clinical trial, University, Pathway, Artificial intelligence, Patient, Diversified Pharmaceutical Services, Legislation, Strategic planning, European Medicines Agency, Analysis, Toronto, Biomarker, Food and Drug Administration, Neurosurgery, Queen's University, Disease, MD, Salvatore DiMasi, SEDAR, MRI, Medication, Italian Medicines Agency, Risk, Research, Stanford University, CSE, Queen, FDA, Algorithm, Medical device, Pharmaceutical industry, Risk management

TORONTO, Dec. 1, 2022 /PRNewswire/ - Nurosene Health Inc. ("Nurosene" or the "Company") (CSE: MEND) (Frankfurt: 8TV) (OTC: MNNDF), a company that is focused on being a leader in the development of Artificial Intelligence (AI) / Machine Learning (ML) solutions targeted at the pharmaceutical industry, is pleased to share the following business update.

Key Points: 
  • TORONTO, Dec. 1, 2022 /PRNewswire/ - Nurosene Health Inc. ("Nurosene" or the "Company") (CSE: MEND) (Frankfurt: 8TV) (OTC: MNNDF), a company that is focused on being a leader in the development of Artificial Intelligence (AI) / Machine Learning (ML) solutions targeted at the pharmaceutical industry, is pleased to share the following business update.
  • The opportunity At Nurosene, we believe there is a significant opportunity to address the very low rate of success in the clinical trial process, by using the NetraAI technology.
  • Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, Nurosene does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.
  • New factors emerge from time to time, and it is not possible for Nurosene to predict all such factors.

NEOconcepts Introduces the Next Generation Nitrogen Plasma Technology with AgeJET

Retrieved on: 
Thursday, December 1, 2022
Eye, Architecture, Skin, Partnership, Physician, Patient, Ageing, MD, Laser, Plasma, Dermatology, Safety, Dermis, Pharmaceutical industry

LEWIS CENTER, Ohio, Dec. 1, 2022 /PRNewswire/ -- NEOconcepts, a leading distributor of aesthetic medical devices for dermatologists, plastic surgeons, and other medical aesthetic providers, has signed an exclusive agreement with Triworks, Palata, Italy, to introduce AgeJET, a revolutionary advancement in nitrogen plasma technology to the U.S. market. AgeJET is a non-ablative, anti-aging skin regeneration therapy that requires just one treatment to realize significant improvement without surgery or downtime.

Key Points: 
  • AgeJET is a non-ablative, anti-aging skin regeneration therapy that requires just one treatment to realize significant improvement without surgery or downtime.
  • A revolutionary advancement in nitrogen plasma technology to the U.S.
    "The U.S. market has never had adequate access to this unique, high-end nitrogen plasma technology.
  • The recent nationwide availability of AgeJET targets an unmet need among physicians in the U.S.," said Matthew Brulport, President and CEO of NEOconcepts.
  • Nitrogen plasma works by exciting nitrogen atoms with ultra-high frequency energy to produce a thermal plasma burst that penetrates into the dermis.

Alan Soroka, MD, is recognized by Continental Who's Who

Retrieved on: 
Thursday, December 1, 2022
Hypertension, Patient, Diagnosis, Internal, Mount Sinai Hospital, University, City, Conditional sentence, American Medical Association, City College of New York, Indian Medical Association, Medical specialty, Bachelor of Science, Physician, Internal medicine, Prime number, MD, Diabetes, Education, City college, Health, Catholic higher education, Continental, Medicine, Health insurance

WINDSOR LOCKS, Conn., Dec. 1, 2022 /PRNewswire/ -- Alan Soroka, MD, being recognized by Continental Who's Who as a Most Trusted Physician in the Medical Field, acknowledging his exemplary work at Prime HealthCare PC.

Key Points: 
  • WINDSOR LOCKS, Conn., Dec. 1, 2022 /PRNewswire/ -- Alan Soroka, MD, being recognized by Continental Who's Who as a Most Trusted Physician in the Medical Field, acknowledging his exemplary work at Prime HealthCare PC.
  • Upon returning to the United States, he completed his residency in internal medicine at Mount Sinai Hospital.
  • Dr. Soroka is one of the founders of HealthCare PC and prides himself on taking time with his patients.
  • According to Dr. Soroka, Internal medicine is the medical specialty dealing with the prevention, diagnosis, and treatment of adult diseases.

Duke T. Matsuyama, MD, is recognized by Continental Who's Who

Retrieved on: 
Thursday, December 1, 2022
Golf, Operation Iraqi Freedom documents, Fleet Marine Force, Multimedia, Laboratory, Health Professions Scholarship Program, California State University, Patient, American Osteopathic College of Radiology, Society, General medical services, Medical Center, Marine Corps Base Camp Lejeune, Camp Fallujah, MD, Fleet Marine Force insignia, United States Department of the Navy, American Osteopathic Association, American Society of Anesthesiologists, Judge Advocate General's Corps, U.S. Navy, Family, A.T. Still University, National Microbiology Laboratory, Continental, Hospital, Medical device, Osteopathic medicine in the United States

Dr. Matsuyama earned a Bachelor of Arts degree in Biological Sciences from California State University, Fullerton, in 1997.

Key Points: 
  • Dr. Matsuyama earned a Bachelor of Arts degree in Biological Sciences from California State University, Fullerton, in 1997.
  • He then earned his Doctor of Osteopathic Medicine Degree at Kirksville College of Osteopathic Medicine in Maryland in 2003.
  • Dr. Matsuyama completed an internship in Osteopathic Medicine and an Anesthesiology residency at Grandview Hospital and Medical Center in Dayton, Ohio.
  • He was awarded Preceptor of the Year in 2018 and recognized with a profile feature in Marquis Who's Who in 2021.

Foresite Labs Appoints Ian Tong, MD and Former Stanford School of Medicine Professor, as Chief Clinical Officer

Retrieved on: 
Thursday, December 1, 2022
DEI (Diversity, Equity and Inclusion), Biotechnology, Data Analytics, Finance, Health, Start-Up, Health Technology, Professional Services, Stanford University School of Medicine, Bias, Health, University, VA Palo Alto Health Care System, Telehealth, Workforce, Foresite Capital, Disease, Internal medicine, Stanford University, National Medical Fellowships, Data science, Pharmaceutical industry, Medicine, Veteran, MD

Today, Foresite Labs announced the addition of Ian Tong, MD to the team as its first chief clinical officer.

Key Points: 
  • Today, Foresite Labs announced the addition of Ian Tong, MD to the team as its first chief clinical officer.
  • Tong will work with Foresite Labs and Foresite Capital to improve access to equitable and effective healthcare at the intersection of technology and care delivery.
  • As a clinical educator at the Stanford University School of Medicine, Tong co-directed the Arbor Free Clinic and pioneered early telemedicine outreach at the Veterans Affairs Palo Alto Health Care System.
  • Tong holds his MD from The University of Chicago-Pritzker School of Medicine and is board certified in Internal Medicine.